Johan Lundberg's research group
Molecular imaging, neuropsychopharmacology, mood and anxiety disorders
The overriding aim of our research is to improve the treatment of major psychiatric disorders. Our main activity involves in vivo and post mortem molecular imaging to study the pathophysiology and pharmacology of mood and anxiety disorders, and to some extent autism spectrum disorders.
One vision of the group is to develop imaging markers for antidepressant treatment response. To this end, we study the molecular effect in man in vivo of different antidepressant treatments, such as Cognitive Behavioral Treatment, antidepressant drug treatment, Electro Convulsive Treatment and novel antidepressant treatments such as ketamine. We have had a focus on the serotonin system, but are performing studies also on the GABA and Glutamate systems. The development of molecular imaging analysis and statistics is an integrated part of our work.
Our work is supported by the Swedish Science Council, the Stockholm County, the Söderström-Königska foundation and from a generous private donation.
|Carl Johan Ekman||Anknuten, Postdoc|
|Johan Lundberg||Anknuten, Forskargruppsledare|
|Mikael Tiger||Anknuten, Postdoc|
|Emma Veldman||Doktorand, Forskarstuderande|